In separate multivariable regression models adjusting for TP53, RB1, or PTEN loss and/or mutation, tumor CNA burden is still associated with overall survival independent of these alterations in primary prostate tumors (Table 3). The gene discussed is TP53; the disease is prostate neoplasm.